BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220829
DTEND;VALUE=DATE:20220902
DTSTAMP:20260516T025628
CREATED:20220527T124300Z
LAST-MODIFIED:20220527T124300Z
UID:34298-1661731200-1662076799@www.pharmajournalist.com
SUMMARY:6th IPF Summit
DESCRIPTION:With two approved therapeutics and the field working to develop the next generation of IPF drugs\, the opportunity to become the undisputed\, most effective\, and disease-modifying agent on the market has never been greater. \nFrom repairing and regenerating lung tissue to illuminating innovative clinical trial design and advance scientific progress; the 6th IPF Summit is your one-stop-shop to supercharge IPF research and drug development. \nWhat’s new and unmissable for 2022: \n\n29 brand new industry speakers\, as well as returning KOLs including Fernando Martinez\, Naftali Kaminski\, Toby Maher\, and many more\n6 interactive workshops to delve into IPF’s hottest topics\, discuss challenges\, pose your burning questions to leading experts\, and highlight the respiratory pipeline development opportunities including SSc-ILD\, COPD\, and COVID fibrosis\nA brand-new Tissue Repair and Regeneration Day\, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities\nExclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development\n\nGet in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie\, Boehringer Ingelheim\, Bayer\, BMS\, Genentech\, Galecto\, Novartis\, and Trevi Therapeutics. \nFrom navigating pathophysiology and pathobiology\, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research. \nTo know more visit: https://ter.li/6yo2nd
URL:https://www.pharmajournalist.com/event/6th-ipf-summit/
LOCATION:Westin Boston Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR